---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-058154"
form_type: "8-K"
ticker: "CERS"
cik: "0001020214"
company_name: "CERUS CORP"
filed_at: "2023-11-02T23:59:59+00:00"
generated_at: "2026-06-08T23:04:54.665043+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# CERS Q3 product revenue $39.8M, net loss $7.3M; FY product revenue guidance cut to $155-158M

## Summary
- Total Q3 revenue $47.3M ($39.8M product, $7.5M govt); net loss $7.3M ($0.04/share) vs $8.5M loss year ago.
- Non-GAAP adjusted EBITDA -$1.0M, improved from -$2.7M; reaffirms Q4 2023 breakeven target.
- Full-year 2023 product revenue guidance revised to $155-158M, citing delay in signing IFC sales agreement.
- Completed Phase 3 ReCePI study enrollment; top-line data expected Q1 2024.
- Cash and investments $79M at Sep 30, down from $102.2M at Dec 31, 2022.

## SEC filing metadata
- accession: 0000950170-23-058154
- form_type: 8-K
- ticker: CERS
- cik: 0001020214
- company_name: CERUS CORP
- filed_at: 2023-11-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1020214/000095017023058154/0000950170-23-058154-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1020214/000095017023058154/cers-20231102.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-058154
- JSON: https://secwatch.observer/filing/0000950170-23-058154.json
- Plain text: https://secwatch.observer/filing/0000950170-23-058154.txt

## Key facts
- Earnings Releases
  CERUS CORP reported third quarter ended September 30, 2023 results: revenue $47.3 million, net income $7.3 million, EPS $0.04 per basic and diluted share. Guidance lowered.
  - Period: third quarter ended September 30, 2023
  - Revenue: $47.3 million
  - Net income: $7.3 million
  - EPS: $0.04 per basic and diluted share
  - Guidance: lowered
  - Result: reported results
  source text: Cerus Corporation (Nasdaq: CERS) today announced financial results for the third quarter ended September 30, 2023. Recent highlights include: • Third quarter 2023 total revenue of $47.3 million was comprised of total product revenue of $39.8 million and government contract revenue of $7.5 million. • Completed Phase 3 ReCePI study enrollment in cardiovascular surgery patients, with top-line data readout on track for Q1 2024. • Attended first in-person AABB Annual Meeting since 2019, where presentations from transfusion medicine leaders highlighted the growing experience with the benefits of INTERCEPT-treated products, including INTERCEPT platelets and INTERCEPT Fibrinogen Complex (IFC). • Cash, cash equivalents, and short-term investments were $79.0 million at September 30, 2023. • Reaffirming commitment to achieve non-GAAP adjusted EBITDA breakeven in the fourth quarter of 2023. “We continued to make progress on multiple fronts in the third quarter,” said William “Obi” Greenman, Cerus’
  evidence_url: https://www.sec.gov/Archives/edgar/data/1020214/000095017023058154/0000950170-23-058154-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.